Telbivudine versus lamivudine in patients with chronic hepatitis B by Bzowej, N et al.
Title Telbivudine versus lamivudine in patients with chronic hepatitisB
Author(s)
Lai, CL; Gane, E; Liaw, YF; Hsu, CW; Thongsawat, S; Wang, Y;
Chen, Y; Heathcote, EJ; Rasenack, J; Bzowej, N; Naoumov, NV;
Di Bisceglie, AM; Zeuzem, S; Moon, YM; Goodman, Z; Chao, G;
Constance, BF; Brown, NA
Citation New England Journal Of Medicine, 2007, v. 357 n. 25, p. 2576-2588
Issued Date 2007
URL http://hdl.handle.net/10722/57525
Rights Creative Commons: Attribution 3.0 Hong Kong License
original article
T h e  n e w  e ng l a nd  j o u r na l  o f  m e dic i n e
n engl j med 357;25 www.nejm.org december 20, 20072576
Telbivudine versus Lamivudine in Patients  
with Chronic Hepatitis B
Ching-Lung Lai, M.D., Edward Gane, M.D., Yun-Fan Liaw, M.D.,  
Chao-Wei Hsu, M.D., Satawat Thongsawat, M.D., Yuming Wang, M.D.,  
Yagang Chen, M.D., E. Jenny Heathcote, M.D., Jens Rasenack, M.D.,  
Natalie Bzowej, M.D., Ph.D., Nikolai V. Naoumov, M.D.,  
Adrian M. Di Bisceglie, M.D., Stefan Zeuzem, M.D.,  
Young Myoung Moon, M.D., Zachary Goodman, M.D.,  
George Chao, Ph.D., Barbara Fielman Constance, R.N.,  
and Nathaniel A. Brown, M.D., for the Globe Study Group*
From the University Department of Med-
icine, Queen Mary Hospital, Hong Kong 
(C.-L.L.); Middlemore Hospital, Auckland, 
New Zealand (E.G.); Chang Gung Memo-
rial Hospital, Chang Gung University Col-
lege of Medicine, Taipei, Taiwan (Y.-F.L., 
C.-W.H.); Chiang Mai University, Chiang 
Mai, Thailand (S.T.); Xi Nan Hospital, Third 
Military Medical University, Chongqing, 
China (Y.W.); First Affiliated Hospital, Zhe-
jiang University, Hangzhou, China (Y.C.); 
University of Toronto, Toronto (E.J.H.); 
Albert Ludwigs University, Freiburg, Ger-
many ( J.R.); Sutter Health, San Francisco 
(N.B.); University College, London (N.V.N.); 
Saint Louis University, St. Louis (A.M.D.); 
Saarland University Hospital, Homburg, 
Germany (S.Z.); Yonsei University College 
of Medicine, Seoul, Korea (Y.M.M.); the 
Armed Forces Institute of Pathology, 
Washington, DC (Z.G.); and Idenix Phar-
maceuticals, Cambridge, MA (G.C., B.F.C., 
N.A.B.). Address reprint requests to Dr. 
Lai at the University Department of Med-
icine, Queen Mary Hospital, Hong Kong, 
China, or at hrmelcl@hkucc.hku.hk.
*The other investigators in the Globe Study 
Group are listed in the Appendix.
N Engl J Med 2007;357:2576-88.
Copyright © 2007 Massachusetts Medical Society.
A BS TR AC T
Background
Reducing hepatitis B virus (HBV) replication to minimal levels is emerging as a key 
therapeutic goal for chronic hepatitis B.
Methods
In this double-blind, phase 3 trial, 1370 patients with chronic hepatitis B were ran-
domly assigned to receive 600 mg of telbivudine or 100 mg of lamivudine once daily. 
The primary efficacy end point was noninferiority of telbivudine to lamivudine for 
therapeutic response (i.e., a reduction in serum HBV DNA levels to fewer than 5 log10 
copies per milliliter, along with loss of hepatitis B e antigen [HBeAg] or normaliza-
tion of alanine aminotransferase levels). Secondary efficacy measures included his-
tologic response, changes in serum HBV DNA levels, and HBeAg responses.
Results
At week 52, a significantly higher proportion of HBeAg-positive patients receiving 
telbivudine than of those receiving lamivudine had a therapeutic response (75.3% vs. 
67.0%, P = 0.005) or a histologic response (64.7% vs. 56.3%, P = 0.01); telbivudine also 
was not inferior to lamivudine for these end points in HBeAg-negative patients. In 
HBeAg-positive and HBeAg-negative patients, telbivudine was superior to lamivudine 
with respect to the mean reduction in the number of copies of HBV DNA from base-
line, the proportion of patients with a reduction in HBV DNA to levels undetectable 
by polymerase-chain-reaction assay, and development of resistance to the drug. Ele-
vated creatine kinase levels were more common in patients who received telbivudine, 
whereas elevated alanine aminotransferase and aspartate aminotransferase levels 
were more common in those who received lamivudine. 
Conclusions
Among patients with HBeAg-positive chronic hepatitis B, the rates of therapeutic 
and histologic response at 1 year were significantly higher in patients treated with 
telbivudine than in patients treated with lamivudine. In both the HBeAg-negative 
and the HBeAg-positive groups, telbivudine demonstrated greater HBV DNA sup-
pression with less resistance than did lamivudine. (ClinicalTrials.gov number, 
NCT00057265.)
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For the approximately 400 million people with chronic hepatitis B virus (HBV) infection, the risk of progression to end-stage 
complications such as cirrhosis and hepatocellular 
carcinoma has been correlated with persistent HBV 
replication, as reflected by serum HBV DNA levels.1 
Correspondingly, prolonged suppression of HBV 
replication with antiviral therapy has been linked 
to reduced risks of end-stage disease manifesta-
tions, a finding that underscores the importance 
of long-lasting HBV suppression as a primary treat-
ment goal.2-9
Multiple types of interferon, lamivudine, adefo-
vir dipivoxil, entecavir, and telbivudine have been 
approved for the treatment of chronic hepatitis B. 
These agents vary with respect to antiviral and 
clinical efficacy, resistance profiles, and tolerabil-
ity and safety.10 For long-term disease manage-
ment, the clinical challenge is to determine how 
to use available agents most effectively to obtain 
consistent, profound, and long-lasting HBV sup-
pression with good safety and convenience in a 
wide variety of health care settings.
Telbivudine (β-l-2′-deoxythymidine) is an orally 
bioavailable l-nucleoside with potent and specific 
anti-HBV activity.11 In preclinical toxicologic test-
ing, telbivudine had no mutagenic or carcinogenic 
effects and no appreciable embryonic or fetal toxic 
effects — findings that are particularly relevant 
for men and women in their reproductive years.12 
In initial clinical trials, treatment with telbivudine 
led to reductions in serum HBV DNA levels that 
were greater than those observed with lamivudine, 
and resistance to telbivudine developed less fre-
quently than did resistance to lamivudine.13,14
The present international phase 3 trial, desig-
nated Globe, compared the safety and efficacy of 
treatment with telbivudine with that of lamivu-
dine, the most widely prescribed anti-hepatitis B 
agent worldwide, in patients with chronic hepati-
tis B. Patients with hepatitis B e antigen (HBeAg)–
positive chronic hepatitis B and those with HBeAg-
negative chronic hepatitis B were evaluated to 
assess differences in therapeutic outcomes that 
may arise as a result of well-recognized differences 
in disease characteristics.10,15-17 Associations be-
tween early suppression of HBV replication and 
subsequent efficacy and resistance outcomes were 
assessed.14,18,19
Me thods
Patients
Men and women between 16 and 70 years of age 
who had HBeAg-positive or HBeAg-negative chron-
ic hepatitis B were eligible to participate in the 
study. The study investigators recruited the patients 
from March 2003 until April 2004 after a review 
of medical records and the completion of screen-
ing procedures to establish their eligibility for the 
trial. Chronic hepatitis B was defined by detect-
able serum hepatitis B surface antigen (HBsAg), 
a serum alanine aminotransferase level 1.3 to 
10.0 times the upper limit of normal, a serum 
HBV DNA level greater than 6 log10 copies per 
milliliter, and compatible pretreatment liver his-
tologic findings.
Exclusion criteria included coinfection with 
hepatitis C, hepatitis D, or the human immuno-
deficiency virus; evidence of hepatic decompen-
sation, pancreatitis, or hepatocellular carcinoma; 
previous treatment for hepatitis B with nucleo-
side or nucleotide analogues or both; treatment 
with interferon or other immunomodulators with-
in the previous 12 months; other forms of liver 
disease; a serum creatinine level greater than 1.5 
mg per deciliter (133 μmol per liter); a serum 
amylase or lipase level greater than 1.5 times the 
upper limit of normal; a prothrombin time pro-
longed by more than 3 seconds; a serum albumin 
level less than 3.3 g per deciliter; and a bilirubin 
level greater than 2.0 mg per deciliter (34 μmol 
per liter). Eligible patients with a serum alpha fe-
toprotein level greater than 50 ng per milliliter 
required exclusion of underlying hepatocellular 
carcinoma.
Study design
This randomized, double-blind, active agent–con-
trolled trial was conducted at 112 academic cen-
ters in 20 countries. Eligible subjects were random-
ly assigned centrally in a 1:1 ratio to receive 600 mg 
of telbivudine or 100 mg of lamivudine once daily 
as oral tablets. Treatment assignments were strat-
ified according to HBeAg status (positive or neg-
ative) and serum alanine aminotransferase level 
(>2.5 or ≤2.5 times the upper limit of normal). 
Within each stratum, patients were randomly as-
signed in block sizes of four. Study drugs were sup-
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plied in bottles containing telbivudine (Idenix 
Pharmaceuticals) or overencapsulated lamivudine 
tablets (GlaxoSmithKline). Primary data analyses 
were specified for a 52-week treatment period, with 
the cohort continuing into a second year for lon-
ger-term assessments.
Patient histories were obtained, physical exami-
nations were conducted, and venipuncture sam-
ples for laboratory assessments were obtained at 
screening, at baseline, and at weeks 2, 4, 8, 12, 16, 
24, 32, 40, 48, and 52. Standardized tests were 
performed centrally by Quintiles Transnational. 
Serum HBV DNA levels were quantified by COBAS 
Amplicor HBV Monitor (Roche Molecular Systems), 
with a detection limit of 300 copies per milliliter. 
Serum samples obtained at screening, baseline, 
and week 2 were prediluted at a 1:1000 ratio to 
ensure that HBV DNA assessments were within 
the assay’s linear range. Liver-biopsy specimens, 
collected before treatment and at week 52, were 
evaluated under blinded conditions by an indepen-
dent expert with the use of the Knodell and Ishak 
histologic scoring systems.20,21
The study was conducted in compliance with 
the ethics principles of the Declaration of Hel-
sinki and was consistent with Good Clinical Prac-
tice guidelines and applicable local regulatory re-
quirements, including institutional-review-board 
approval. All patients provided written informed 
consent. The informed-consent forms discussed 
alternative treatment with interferon, lamivudine, 
and adefovir dipivoxil in countries where these 
therapies were available. Clinical data were col-
lected and monitored by Quintiles. The sponsors, 
Idenix Pharmaceuticals and Novartis Pharmaceu-
ticals, conducted predefined statistical analyses; 
the investigators had full access to the data and 
contributed substantially to study design, data col-
lection, and data analysis. The manuscript was 
written in collaboration by the first and last au-
thors; all the other authors were actively involved 
in review of the manuscript and approval of the 
final version. The academic authors vouch for the 
veracity and completeness of the data and data 
analyses.
Study End points
The primary efficacy end point was therapeutic re-
sponse, defined as a reduction in the serum HBV 
DNA level to fewer than 5 log10 copies per milli-
liter, as recommended in available treatment guide-
lines,22,23 coupled with either normalization of the 
alanine aminotransferase level or loss of detect-
able HBeAg. This composite end point captures 
indicators of liver disease and viral suppression 
used in clinical practice, similar to composite end 
points used in previous interferon and lamivudine 
trials.24-28
Histologic response, the key secondary efficacy 
end point, was defined as a reduction of at least 
two points in the Knodell necroinflammatory 
score, with no worsening in the Knodell fibrosis 
score. Other secondary efficacy measures includ-
ed changes in the serum HBV DNA level, HBeAg 
and HBsAg loss and seroconversion, virologic re-
sponse (a serum HBV DNA level below 5 log10 
copies per milliliter and HBeAg loss),29 and nor-
malization of the serum alanine aminotransfer-
ase level. Primary treatment failure was defined 
as completion of at least 24 weeks of treatment 
without two consecutive measurements of serum 
HBV DNA levels below 5 log10 copies per milliliter. 
Safety evaluations included discontinuation of the 
study drug and analyses of adverse events and 
graded laboratory abnormalities.
HBV genotyping, viral breakthrough,  
and resistance
Viral breakthrough was defined as at least two 
consecutive determinations of an increase in HBV 
DNA by at least 1 log10 copy per milliliter from 
nadir during 48 weeks of therapy, a definition con-
sistent with recent recommendations.30,31 Resis-
tance was defined as viral breakthrough with treat-
ment-emergent resistance mutations.31 HBV DNA 
was amplified by polymerase chain reaction (PCR) 
from serum samples at screening or at baseline 
from all patients, serum samples at week 48 from 
patients with viral breakthrough, and from pa-
tients who received telbivudine and who had more 
than 3 log10 copies of residual HBV DNA per mil-
liliter at week 52. The 344-codon reverse transcrip-
tase domain of the HBV polymerase gene was 
sequenced at an independent laboratory (Delft 
Diagnostic Laboratory). This automated method 
detects potential resistance mutations that com-
prise at least 25% of the amplified viral DNA and 
is consistent with previous methods.32-35
early antiviral response versus subsequent 
outcomes
Prespecified analyses assessed relationships be-
tween early antiviral responses and efficacy and 
resistance outcomes at 1 year. Patients were cat-
egorized at week 24 according to PCR analysis as 
being negative for serum HBV DNA, as having de-
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tectable but fewer than 3 log10 copies of HBV DNA 
per milliliter, as having from 3 to 4 log10 copies 
per milliliter, or as having more than 4 log10 cop-
ies per milliliter.
Statistical analysis
The study design provided 99% power to demon-
strate noninferiority of telbivudine to lamivudine 
for therapeutic response, assuming a noninferi-
ority criterion of 15 percentage points, with en-
rollment of at least 600 HBeAg-positive and 400 
HBeAg-negative patients. Analyses were based on 
all patients randomly assigned to treatment who 
received at least one dose of study medication. 
Analyses of histologic response included all pa-
tients with pretreatment liver-biopsy specimens 
that could be evaluated, as in previous studies.32-35 
The primary analysis occurred at week 52, with 
longer-term assessments at week 104. An indepen-
dent data and safety monitoring board and an ex-
ternal data-analysis center monitored safety. The 
patients, investigators, and sponsor remained un-
aware of treatment assignments throughout the 
study.
The study was intended to demonstrate effects 
in both HBeAg subpopulations or in the pooled 
population, if trends in the subpopulations war-
ranted pooling. The primary end point was as-
sessed by a three-step method.36 First, both HBeAg 
subpopulations were analyzed separately with an 
alpha level of 0.04 (95.68% confidence interval). 
If both subpopulations met the noninferiority cri-
teria (i.e., if confidence intervals for the treatment 
difference exceeded –15%), treatments would be 
compared for superiority within each subpopula-
tion. If statistical significance was not established 
within both HBeAg subpopulations, a statistical 
test for interaction between the treatment group 
and HBeAg subpopulations was planned, with 
significance defined at the alpha level of 0.15.37 
With no interaction, a statistical analysis for the 
overall patient population would be performed 
with an alpha level of 0.000933 to protect the over-
all alpha at 0.00125.
Demonstration of noninferiority was a precur-
sor to superiority testing. For the primary efficacy 
end point, noninferiority criteria were met in both 
HBeAg subpopulations, but superiority was not 
established for the primary end point in the 
HBeAg-negative population. HBeAg subpopula-
tions were not pooled because of this statistical 
interaction between treatment effect and HBeAg 
subpopulation. For secondary end points, treat-
ment effects were compared, first for noninferi-
ority and then for superiority, according to a pre-
specified hierarchy.
Treatment comparisons of categorical end points 
were assessed by a weighted Cochran–Mantel–
Haenszel method adjusted for randomization stra-
ta. For continuous variables, analysis of variance 
was performed with each stratified group as a 
factor. Reported P values are two-sided and were 
not adjusted for multiple testing.
R esult s
Patients
Six hundred eighty-three patients were assigned 
to receive telbivudine and 687 to receive lamivu-
dine; 3 patients declined to participate further af-
ter undergoing randomization. The intention-to-
treat population consisted of 921 patients with 
HBeAg-positive chronic hepatitis B and 446 pa-
tients with HBeAg-negative chronic hepatitis B. 
The treatment groups were well matched at base-
line for demographic and disease characteristics 
(Table 1). Eighteen patients receiving telbivudine 
(2.6%) and 32 receiving lamivudine (4.7%) with-
drew before week 52. Among these, two in the 
telbivudine group (0.3%) and eight in the lamivu-
dine group (1.2%) discontinued treatment because 
of adverse events, clinical disease progression, or 
lack of efficacy. Two of these patients — one with 
myopathy in the telbivudine group and one with 
urticaria in the lamivudine group — discontinued 
treatment because of serious adverse events that 
possibly were related to the study drugs.
Therapeutic and Histologic Responses
For all study end points, noninferiority criteria 
were met for telbivudine as compared with lami-
vudine, allowing for superiority testing. Among 
HBeAg-positive patients at week 52, significantly 
more patients in the telbivudine group than in the 
lamivudine group had either a therapeutic or a 
histologic response (Table 2). Among HBeAg-neg-
ative patients, the rates of therapeutic and histo-
logic response were similar in both treatment 
groups at week 52, and thus the noninferiority cri-
teria were met.
HBV DNA Responses
Among both HBeAg-positive patients and HBeAg-
negative patients, reduction in serum HBV DNA 
Copyright © 2007 Massachusetts Medical Society. All rights reserved. 
Downloaded from www.nejm.org at UNIVERSITY OF HONG KONG LIBRARIES on May 22, 2009 . 
T h e  n e w  e ng l a nd  j o u r na l  o f  m e dic i n e
n engl j med 357;25 www.nejm.org december 20, 20072580
levels at week 52 was significantly greater in the 
telbivudine group than in the lamivudine group 
(Table 2). The difference was evident by week 12 
in HBeAg-positive patients (reductions of 5.71 log10 
copies per milliliter for telbivudine and 5.42 log10 
copies per milliliter for lamivudine, P = 0.01) and 
by week 8 in HBeAg-negative patients (reductions 
of 4.36 log10 copies per milliliter for telbivudine 
and 4.08 log10 copies per milliliter for lamivudine, 
P = 0.02), and it persisted through week 52 (Fig. 
1A and 1B).
At week 52, the proportion of patients in whom 
Table 1. Baseline Characteristics.*
Characteristic HBeAg-Positive Patients HBeAg-Negative Patients
Telbivudine
(N = 458)
Lamivudine
(N = 463)
Telbivudine
(N = 222)
Lamivudine
(N = 224)
Years of age — mean (range) 32 (16–63) 33 (16–67) 43 (17–68) 43 (18–68)
Male sex — no. (%) 333 (73) 351 (76) 174 (78) 177 (79)
Weight in kg — mean (range) 66 (38–126) 68 (38–150) 72 (42–123) 71 (45–148)
Race or ethnic group — no. (%)†
Chinese 265 (57.9) 265 (57.2) 116 (52.3) 102 (45.5)
Non-Chinese Asian 115 (25.1) 106 (22.9) 29 (13.1) 42 (18.8)
White 52 (11.4) 55 (11.9) 46 (20.7) 56 (25.0)
Black 4 (0.9) 7 (1.5) 3 (1.4) 3 (1.3)
Latino 2 (0.4) 4 (0.9) 2 (0.9) 4 (1.8)
Middle Eastern or Indian 8 (1.7) 7 (1.5) 6 (2.7) 4 (1.8)
Other 12 (2.6) 19 (4.1) 20 (9.0) 13 (5.8)
HBV genotype — no. (%)
A 24 (5.2) 31 (6.7) 12 (5.4) 14 (6.2)
B 129 (28.2) 113 (24.4) 59 (26.6) 59 (26.3)
C 259 (56.6) 258 (55.7) 89 (40.1) 86 (38.4)
D 42 (9.2) 54 (11.7) 57 (25.7) 64 (28.6)
Other or unknown 4 (0.9) 7 (1.5) 5 (2.3) 1 (0.4)
Serum alanine aminotransferase — IU/liter‡
Mean 146.4±5.37 158.9±6.30 137.0±6.94 143.7±8.74
Median (range) 111.0 (19–1137) 111.0 (25–1133) 99.0 (31–569) 98.5 (12–982)
Serum HBV DNA — log10 copies/ml
Mean 9.5±0.09 9.5±0.09 7.7±0.12 7.4±0.10
Median (range) 9.6 (3.8–16.0) 9.6 (3.6–16.1) 7.2 (3.0–13.0) 7.1 (3.7–12.1)
Liver histologic findings§
Mean total Knodell Histologic Activity 
Index score
8.9 9.0 9.0 9.6
Mean Knodell necroinflammatory score 7.4 7.3 7.3 7.6
Mean Ishak fibrosis score 2.1 2.2 2.3 2.5
* HBeAg denotes hepatitis B e antigen, and HBV hepatitis B virus. Plus–minus values are means ±SE.
† Race or ethnic group was self-assessed.
‡ The upper limit of normal for serum alanine aminotransferase was 48 IU per liter for men and 37 IU per liter for  
women.
§ The analysis included the 872 HBeAg-positive patients (94.7% of the total intention-to-treat population) with baseline 
liver-biopsy findings that could be evaluated. The Knodell Histologic Activity Index score can range from 0 to 22, with 
higher scores indicating more severe disease. The Knodell inflammatory score can range from 0 to 18, with higher 
scores indicating more severe chronic hepatitis. The Ishak fibrosis score is based on a scale of 0 to 6, where 0 indicates 
no fibrosis and 5 or higher indicates cirrhosis.
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serum HBV DNA levels were undetectable by 
PCR assay was significantly greater in the telbivu-
dine group than in the lamivudine group among 
HBeAg-positive patients (60.0% vs. 40.4%, P<0.001) 
and HBeAg-negative patients (88.3% vs. 71.4%, 
P<0.001) (Table 2). The mean time required for 
serum HBV DNA to become undetectable by PCR 
assay was significantly shorter in the telbivudine 
group than in the lamivudine group among 
HBeAg-positive patients (34 weeks vs. 39 weeks, 
P<0.001) and HBeAg-negative patients (20 weeks 
vs. 26 weeks, P<0.001) (Fig. 1C and 1D). Primary 
treatment failure was less frequent with telbivu-
dine than with lamivudine among both HBeAg-
positive and HBeAg-negative patients, but the dif-
ference was significant only for HBeAg-positive 
patients (Table 2).
HBeAg and HBsAg Responses
Among HBeAg-positive patients, 25.7% of those 
in the telbivudine group and 23.3% of those in 
the lamivudine group had HBeAg loss (P = 0.40) 
and 22.5% of those in the telbivudine group and 
21.5% of those in the lamivudine group had HBeAg 
seroconversion (P = 0.73) (Table 2). Among the 69% 
of patients with pretreatment alanine aminotrans-
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Figure 1. Serum HBV DNA Levels from Baseline to Week 52.
Serum samples were analyzed for HBV DNA content. The lower limit of detection of the assay was 300 copies per 
milliliter. Panels A and B show the reduction of serum HBV DNA levels from baseline to week 52, plotted as mean 
(±SE) log10 change from baseline values. For patients with HBeAg-positive chronic hepatitis B, the data represent 
the means for 457 and 462 patients in the telbivudine and lamivudine groups, respectively, at baseline, and for 443 
and 444 patients in the telbivudine and lamivudine groups, respectively, at week 52. For patients with HBeAg-nega-
tive chronic hepatitis B, the data represent the means for 221 and 224 patients in the telbivudine and lamivudine 
groups, respectively, at baseline, and for 219 patients in each treatment group at week 52. Panels C and D show the 
proportion of patients with undetectable levels of HBV DNA according to polymerase-chain-reaction (PCR) assays, 
maintained from the point of first occurrence through week 52. 
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ferase levels at least twice the upper limit of nor-
mal — a group generally considered the best can-
didates for treatment22,23 — HBeAg loss occurred 
in 30.8% and 26.2% of patients receiving telbivu-
dine and lamivudine, respectively (P = 0.22), and 
HBeAg seroconversion occurred in 26.6% and 
24.1%, respectively (P = 0.49). Less than 1% of pa-
tients in each treatment group had HBsAg sero-
conversion.
Biochemical Response
The rates of normalization of serum alanine ami-
notransferase at week 52 were high (levels more 
than 70%) in both treatment groups, with results 
meeting noninferiority criteria in the HBeAg-
positive and in the HBeAg-negative subgroups 
(Table 2).
Additional Histologic Analyses
Among HBeAg-positive patients, the mean Knodell 
Histologic Activity Index scores (range, 0 to 22, 
with higher scores indicating more severe disease) 
improved by 3.92 and 3.64 points in patients re-
ceiving telbivudine and in those receiving lami-
vudine, respectively (difference, 0.28; 95% con-
fidence interval [CI], –0.23 to 0.79); among 
HBeAg-negative patients, the scores improved by 
3.85 and 3.73 points, respectively (difference, 0.12; 
95% CI, –0.59 to 0.82). Among HBeAg-positive pa-
tients with marked pretreatment bridging fibro-
sis or cirrhosis and who had Ishak fibrosis scores 
of 4 to 6 (where 0 indicates no fibrosis and 6 in-
dicates cirrhosis), the Ishak fibrosis scores im-
proved to between 0 and 3 in 68% of patients 
receiving telbivudine and 61% of patients receiv-
ing lamivudine (difference, 7%; 95% CI, –16 to 
29%); the corresponding figures for HBeAg-neg-
ative patients were 59% and 46% (difference, 13%; 
95% CI, –14 to 40%). In contrast, among patients 
with baseline Ishak fibrosis scores of 0 to 3, pro-
gression to a score greater than 3 by week 52 oc-
curred in only 1% of patients in either HBeAg 
subgroup who were taking either telbivudine or 
lamivudine. 
Breakthrough and Resistance
Viral breakthrough and genotypic resistance were 
significantly less common in patients receiving 
telbivudine than in those receiving lamivudine (Ta-
ble 2). Resistance developed in 5.0% and 2.3% of 
HBeAg-positive and HBeAg-negative patients who 
received telbivudine, respectively, as compared with 
11.0% and 10.7% of HBeAg-positive and HBeAg-
negative patients who received lamivudine, re-
spectively (P<0.001 for both comparisons).
Consistent with previous reports, M204I was 
the only signature mutation associated with tel-
bivudine resistance; secondary mutations L80I/V 
and L80I/V + L180M accompanied M204I in 2.2% 
and 0.3%, respectively, of the patients who re-
ceived telbivudine.14,38,39 Overall, the M204I mu-
tation was detected in 46 of the 115 patients who 
received telbivudine and who had serum HBV DNA 
levels of at least 1000 copies per milliliter at 
week 52 (including patients with viral break-
through), representing 6.8% of all telbivudine re-
cipients in the study. Variants harboring mutations 
at the A181 and L229 codons were detected spo-
radically, with 16 and 6 occurrences, respectively, 
among the 115 telbivudine recipients with de-
tectable HBV DNA, but these were not associated 
with viral breakthrough without concomitant de-
tection of M204I. Lamivudine resistance was based 
on the signature mutations M204I and M204V; 
M204V was accompanied by the L180M second-
ary mutation, whereas M204I was seen alone or 
with the secondary mutation L80I/V.31,39
Early Viral Suppression and 1-Year Efficacy 
Outcomes
The distribution of patients according to HBV DNA 
levels at week 24 (Fig. 2) is consistent with the 
greater viral suppression observed with telbivu-
dine (Fig. 1). At week 24, more patients in the tel-
bivudine group than in the lamivudine group were 
negative for HBV DNA according to PCR, where-
as residual HBV DNA levels greater than 4 log10 
copies per milliliter were more frequent in patients 
in the lamivudine group than in those in the tel-
bivudine group.
In the combined treatment groups, low HBV 
DNA levels at week 24 were associated with fa-
vorable 1-year efficacy outcomes (Fig. 3A). Of 
HBeAg-positive patients at week 24, 41% with un-
detectable levels of HBV DNA on PCR underwent 
seroconversion by week 52 as compared with 4% 
of patients with more than 4 log10 copies of HBV 
DNA per milliliter. Similar correlations were ob-
served between HBV DNA levels at week 24 and 
the proportion of patients with alanine transami-
nase normalization at week 52.
At week 24, in HBeAg-positive patients in both 
treatment groups combined, resistance occurred 
in only 2% of patients who were negative for HBV 
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DNA on PCR, as compared with 15% of patients 
with viral loads above 4 log10 copies per milliliter 
(Fig. 3A). A similar pattern was evident for HBeAg-
negative patients. The pattern of relationships be-
tween HBV DNA levels at week 24 and subsequent 
resistance was similar for telbivudine and lamivu-
dine. However, viral suppression was significantly 
greater and resistance was less frequent in the 
telbivudine group than in the lamivudine group 
within each viral-load category at week 24 (Fig. 
3B). Multivariate regression analyses identified vi-
ral load at week 24 as the most significant pre-
dictor of 1-year efficacy outcomes and resistance.
Safety and adverse events
The frequencies of adverse events through week 
52 were similar for patients who received telbivu-
dine and for those who received lamivudine (Ta-
ble 3). Serious adverse events (defined according 
to criteria adapted from the Division of AIDS, 
National Institute of Allergy and Infectious Dis-
eases40), regardless of attributability to study 
drug, were reported for 18 patients in the telbi-
vudine group (2.6%) and 33 in the lamivudine 
group (4.8%).
Elevations in creatine kinase levels through 
week 52 were more common in recipients of tel-
bivudine than in recipients of lamivudine (Table 3). 
Creatine kinase levels were elevated in 15% of 
study patients before treatment, a finding consis-
tent with the frequent elevations in creatine kinase 
levels reported in patients who received placebo 
in previous studies.32,34,41 Grade 3 or 4 elevations 
in creatine kinase levels (at least seven times the 
upper limit of normal), which were observed in 
7.5% of patients in the telbivudine group and 3.1% 
of those in the lamivudine group, decreased spon-
taneously during drug treatment to grade 2 or 
lower by the next visit in 66.7% of the patients 
in the telbivudine group and 73.9% of those in 
the lamivudine group. Patterns of clinical adverse 
events, including infrequent muscle-related symp-
toms, correlated poorly with elevations in creatine 
kinase levels and were similar in the two study 
groups. Myopathy, characterized by muscle pain 
and weakness and moderately elevated creatine 
kinase levels before and during treatment, was 
reported in one patient 11 months after initiation 
of telbivudine. When telbivudine was discontin-
ued, creatine kinase levels returned to normal 
within 1 month and symptoms resolved over a 
period of 9 to 12 months.
Grade 3 or 4 elevations in alanine aminotrans-
ferase and aspartate aminotransferase levels dur-
ing treatment were less frequent in the telbivudine 
group than in the lamivudine group (Table 3). 
Grade 3 or 4 elevations in alanine aminotrans-
ferase levels were noted in 13.1% of patients re-
ceiving lamivudine and 12.5% of patients receiv-
ing telbivudine who had viral breakthrough. One 
patient with lamivudine resistance had liver fail-
ure and received a liver transplant. After week 24, 
alanine aminotransferase flares of at least 500 IU 
per liter and at least twice the baseline value were 
more common with lamivudine (2.2%) than tel-
bivudine (0.4%).
Discussion
In patients with HBeAg-positive chronic hepati-
tis B, telbivudine was superior to lamivudine for 
the primary and key secondary efficacy end points 
of therapeutic response and histologic response; 
in HBeAg-negative patients, telbivudine and lami-
vudine achieved similar rates of therapeutic and 
histologic response. In both HBeAg-positive and 
HBeAg-negative patients, telbivudine had greater 
antiviral efficacy than did lamivudine. The mech-
anism underlying the effect of pretreatment HBeAg 
status on therapeutic and histologic response is 
uncertain, but it may derive from the lower base-
line HBV DNA levels and high viral clearance 
rates observed in HBeAg-negative patients. Re-
sults may differ with longer-term follow-up, as 
treatment-related differences in antiviral potency 
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Figure 2. Serum HBV DNA Levels after 24 Weeks of Treatment.
The distribution of patients with HBeAg-positive chronic hepatitis B and 
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total 100. 
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and resistance assume greater importance for de-
termining therapeutic outcomes.
The lower resistance rates observed with telbi-
vudine than with lamivudine are probably due in 
part to the greater antiviral efficacy of telbivu-
dine. Consistent with in vitro findings, data con-
cerning clinical resistance confirm the M204I 
mutation as the primary basis for telbivudine re-
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Figure 3. Effect of Early Viral Suppression on Treatment Outcomes.
The outcomes at week 48 (i.e., resistance) or week 52 (i.e., HBeAg seroconversion, alanine aminotransferase nor-
malization, or undetectable levels of HBV DNA according to PCR assay) were assessed according to the category of 
residual viral load at week 24. Panel A shows the percentage of patients within each viral-load category at week 24  
in whom the indicated efficacy end points were achieved at 1 year. Data are presented for the combined telbivudine 
and lamivudine treatment groups. Panel B shows the percentage of patients within each viral-load category at week 
24 in whom resistance developed by 1 year, according to treatment group. HBV denotes hepatitis B virus, and 
HBeAg hepatitis B e antigen.
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sistance, in contrast to lamivudine resistance, 
which is associated with either the M204I or the 
M204V mutation.38 HBV with either of these mu-
tations is less susceptible to inhibition by nucle-
oside analogues but remains sensitive in vitro to 
the nucleotide analogues adefovir and tenofovir.31
This study confirms previously described as-
sociations between greater reductions in HBV DNA 
levels at week 24 and better subsequent therapeu-
tic outcomes, including lower resistance.14,18,19 
These relationships were similar for both study 
drugs and may also apply to other agents for 
hepatitis B. The greater viral suppression achieved 
with more potent drugs predicts improved clini-
cal outcomes overall.8,10 Future studies of patients 
with suboptimal responses may determine wheth-
er early treatment modification, using drugs with 
complementary resistance profiles, can improve 
subsequent outcomes.
The adverse event data in this trial were con-
sistent with previous findings and preclinical toxi-
cologic data12,14,42 and suggest that telbivudine 
and lamivudine have similar safety profiles. On-
treatment aminotransferase flares after the first 
6 months of treatment were less frequent with 
telbivudine, in accord with the lower incidence of 
viral breakthrough. Elevations in creatine kinase 
levels were more frequent with telbivudine but 
were not predictive of muscle-related adverse 
events. The occurrence of myopathy in a patient 
treated with telbivudine suggests that any persis-
tent, unexplained muscle-related symptoms should 
be evaluated promptly.
As for all agents, the clinical role of telbivu-
dine will be determined by efficacy, safety, and 
resistance considerations. Lamivudine was cho-
sen as the comparator in this trial because it was 
the treatment of choice when the trial was initi-
ated. Telbivudine has not been compared di-
rectly with other recently approved agents, such 
as entecavir. However, in separate trials, both 
telbivudine and entecavir have shown greater 
antiviral effects than have adefovir and lamivu-
dine.33,35,43,44 One year of treatment with pegylated 
interferon has also been shown to be superior to 
1 year of lamivudine when efficacy is assessed 
24 weeks after both agents have been stopped.24,25 
However, we are unaware of any trials that have 
compared the efficacy of 1 year of pegylated in-
terferon with that of longer-term treatment with 
nucleoside or nucleotide analogues.
Maintaining safety and antiviral efficacy is 
critical with extended therapy. Loss of response 
due to cumulative resistance, treatment failure, 
or both has been observed with all nucleoside or 
nucleotide therapies for hepatitis B. Within 4 years 
after initiation of treatment, the cumulative inci-
dence of lamivudine resistance approaches 70%.39 
Adefovir resistance was observed in 29% of HBeAg-
negative patients after 5 years of treatment and 
in 16 of 38 HBeAg-positive patients with viro-
logic failure after 110 to 279 weeks.45 With en-
tecavir, cumulative resistance was 0.8% at 4 years 
Table 3. Clinical Adverse Events and Laboratory Abnormalities to Week 52.
Event
Telbivudine
(N = 680)
Lamivudine
(N = 687)
Clinical adverse events — %*
Any adverse event 73 69
Upper respiratory tract infection 12 12
Headache 10 12
Nasopharyngitis 10 10
Fatigue 10 9
Increased blood creatine kinase 8 6
Postprocedure pain 6 5
Cough 6 6
Upper abdominal pain 5 7
Influenza 5 5
Diarrhea 5 4
Nausea 5 4
Dizziness 4 5
Dyspepsia 2 5
Grade 3 or 4 laboratory abnormalities 
— no. (%)†
Alanine aminotransferase 25 (3.7) 43 (6.3)
Aspartate aminotransferase 18 (2.6) 32 (4.7)
Creatine kinase 51 (7.5) 21 (3.1)
Lipase 12 (1.8) 22 (3.2)
Amylase 1 (0.1) 2 (0.3)
Absolute neutrophil count 13 (1.9) 9 (1.3)
Platelet count 5 (0.7) 4 (0.6)
Total bilirubin 0 2 (0.3)
* All clinical adverse events occurring in at least 5% of patients in either treat-
ment group are listed, regardless of their attributability to the study drug.
† The severity of laboratory abnormalities was graded according to criteria adapt-
ed from the Division of AIDS, National Institute of Allergy and Infectious Dis-
eases.40 Grade 3 elevations in aminotransferase levels are those 3 to 10 times 
baseline; grade 4 elevations in aminotransferase levels are those at least 10 times 
baseline or accompanied by evidence of hepatic failure. Grades 3 and 4 elevations 
in creatine kinase levels are those at least 7 times the upper limit of normal.
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according to an analysis of 120 of the 663 pa-
tients not previously treated with nucleosides from 
phase 3 trials.46 Similarly, cumulative telbivu-
dine resistance is likely to increase as therapy is 
extended. Long-term studies are needed to un-
derstand the cumulative prevalence and clinical 
effect of resistance to these agents.
The multiple therapeutic choices now available 
for hepatitis B will enhance the ability of clini-
cians to maintain long-term control of HBV rep-
lication, ultimately improving clinical outcomes 
for more patients. These results support telbivu-
dine as an effective therapy for patients with 
chronic hepatitis B.
Supported by Idenix Pharmaceuticals and Novartis Pharma-
ceuticals.
Dr. Lai reports receiving consulting fees from Bristol-Myers 
Squibb, Idenix Pharmaceuticals, and GlaxoSmithKline, lecture 
fees from Bristol-Myers Squibb, Idenix Pharmaceuticals, and 
GlaxoSmithKline, and grant support from Bristol-Myers Squibb, 
Idenix Pharmaceuticals, and Novartis Pharmaceuticals; Dr. Gane, 
consulting fees from Idenix Pharmaceuticals, Novartis Pharma-
ceuticals, and GlaxoSmithKline and lecture fees from Novartis 
Pharmaceuticals and GlaxoSmithKline; Dr. Liaw, consulting fees 
from Bristol-Myers Squibb, Roche, Schering-Plough, and Novar-
tis, lecture fees from Bristol-Myers Squibb and Novartis, and 
grant support from Roche, Bristol-Myers Squibb, Novartis, and 
SciClone Pharmaceuticals; Dr. Heathcote, consulting fees from 
Idenix Pharmaceuticals and Novartis Pharmaceuticals and grant 
support from Idenix Pharmaceuticals, Gilead Sciences, Debio, 
Schering-Plough Pharmaceuticals, Vertex Pharmaceuticals, Hu-
man Genome Sciences, Roche, Pharmasett, and Novartis; and Dr. 
Bzowej, consulting fees from Idenix Pharmaceuticals and Gilead 
Sciences, lecture fees from Idenix Pharmaceuticals and Novartis 
Pharmaceuticals, and grant support from Idenix Pharmaceuti-
cals, Gilead Sciences, Roche, Novartis Pharmaceuticals, Vertex 
Pharmaceuticals, GlaxoSmithKline, and Schering-Plough. Dr. 
Naoumov reports being an employee of Novartis Pharmaceuticals 
and receiving consulting fees from Gilead Sciences, Roche, Idenix 
Pharmaceuticals, and Novartis Pharmaceuticals, lecture fees 
from GlaxoSmithKline, Schering-Plough, Idenix Pharmaceuti-
cals, and Novartis Pharmaceuticals, and grant support from Ide-
nix Pharmaceuticals and Gilead Sciences. Dr. Di Bisceglie reports 
receiving consulting fees from Idenix Pharmaceuticals, Roche, 
Novartis Pharmaceuticals, Vertex Pharmaceuticals, Bristol-Myers 
Squibb, Pharmasset, Metabasis Therapeutics, SciClone Pharma-
ceuticals, and Chiron Corporation and grant support from Roche 
Pharmaceuticals, Gilead Sciences, and Vertex Pharmaceuticals; 
Dr. Zeuzem, consulting fees from Gilead Sciences, Roche, Idenix 
Pharmaceuticals, and Novartis Pharmaceuticals and lecture fees 
from Bristol-Myers Squibb, Gilead Sciences, Roche, Idenix Phar-
maceuticals, and Novartis Pharmaceuticals; and Dr. Goodman, 
consulting fees from Schering-Plough and Gilead Sciences and 
grant support from Idenix Pharmaceuticals, Bristol-Myers Squibb, 
SciClone Pharmaceuticals, New England Research Institutes, and 
GlaxoSmithKline. Dr. Chao reports having been an employee of 
Idenix Pharmaceuticals until June 2006 and holding equity in 
Idenix Pharmaceuticals and Bristol-Myers Squibb. Dr. Brown re-
ports being a former employee of Idenix Pharmaceuticals and 
holding equity in Idenix Pharmaceuticals. Ms. Fielman Constance 
reports being a full-time employee of Idenix Pharmaceuticals and 
holding equity in Idenix Pharmaceuticals. No other potential 
conflict of interest relevant to this article was reported.
We thank Richard Boehme, Ph.D., for assistance with manu-
script preparation.
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Niu, B. Prabhakar, R.R. Rai, S.K. Sarin, E.K. Teo, M. Wan, S.M. Wu, D.Z. Xu, J.Z. Xu, W.L. Yang, Y.K. Yin, X.Q. Zhou, L. Zhu; Austra-
lia and New Zealand — P. Angus, D. Crawford, G. Farrell, J. George, C. Moyes, S. Roberts, W. Sievert, S. Strasser, F. Weilert.
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